{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:47:35Z","timestamp":1793908055900,"version":"4.8.0"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.obpill.2023.100056","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T22:04:33Z","timestamp":1674857073000},"page":"100056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-1408","authenticated-orcid":false,"given":"Harold Edward","family":"Bays","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagun","family":"Bindlish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany Lowe","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.obpill.2023.100056_bib1","author":"Bays"},{"key":"10.1016\/j.obpill.2023.100056_bib2","article-title":"Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022","volume":"1","author":"Fitch","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib3","article-title":"Thirty obesity myths, misunderstandings, and\/or oversimplifications: an obesity medicine association (OMA) clinical practice statement (CPS) 2022","volume":"3","author":"Bays","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","article-title":"Why does obesity cause diabetes?","volume":"34","author":"Klein","year":"2022","journal-title":"Cell Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/14796678.1.1.39","article-title":"Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia","volume":"1","author":"Bays","year":"2005","journal-title":"Future Cardiol"},{"key":"10.1016\/j.obpill.2023.100056_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/17460875.1.4.389","article-title":"Adiposopathy: why do adiposity and obesity cause metabolic disease?","volume":"1","author":"Bays","year":"2006","journal-title":"Future Lipidol"},{"key":"10.1016\/j.obpill.2023.100056_bib7","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.amjmed.2008.10.015","article-title":"Sick fat,\" metabolic disease, and atherosclerosis","volume":"122","author":"Bays","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.obpill.2023.100056_bib8","doi-asserted-by":"crossref","first-page":"4B","DOI":"10.1016\/j.amjcard.2012.08.029","article-title":"Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating \"sick fat\" through improving fat function with antidiabetes therapies","volume":"110","author":"Bays","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.obpill.2023.100056_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11883-014-0409-1","article-title":"Adiposopathy, \"sick fat,\" Ockham's razor, and resolution of the obesity paradox","volume":"16","author":"Bays","year":"2014","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.obpill.2023.100056_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/ALN.0b013e3181799d45","article-title":"Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms","volume":"109","author":"Martyn","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1016\/j.obpill.2023.100056_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3788","article-title":"Association between obesity and cardiovascular outcomes: a systematic review and meta-analysis of mendelian randomization studies","volume":"1","author":"Riaz","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.obpill.2023.100056_bib12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dci17-0057","article-title":"Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care","volume":"41","author":"Cefalu","year":"2018","journal-title":"Expert Forum Diabetes care"},{"key":"10.1016\/j.obpill.2023.100056_bib13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12933-017-0610-y","article-title":"Updates on cardiovascular outcome trials in diabetes","volume":"16","author":"Schnell","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.obpill.2023.100056_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.obpill.2022.100044","article-title":"Obesity pillars roundtable: body mass index and body composition in black and female individuals. Race-relevant or racist? Sex-relevant or sexist?","author":"Bays","year":"2022","journal-title":"Obes Pillars"},{"issue":"6","key":"10.1016\/j.obpill.2023.100056_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.hjc.2018.11.008","article-title":"GLP-1 receptor agonists and cardiovascular outcome trials: an update","volume":"60","author":"Andrikou","year":"2019","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.obpill.2023.100056_bib16","article-title":"Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes","volume":"1","author":"O'Brien","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.obpill.2023.100056_bib17","article-title":"Sulfonylurea is associated with higher risks of ventricular arrhythmia or sudden cardiac death compared with metformin: a population-based cohort study","volume":"11","author":"Lee","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.obpill.2023.100056_bib18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.pcad.2017.09.001","article-title":"Insulin therapy increases cardiovascular risk in type 2 diabetes","volume":"60","author":"Herman","year":"2017","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.obpill.2023.100056_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/14791641221093175","article-title":"Impact of insulin therapy on outcomes of diabetic patients with heart failure: a systematic review and meta-analysis","volume":"19","author":"Liu","year":"2022","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.obpill.2023.100056_bib20","article-title":"Anti-obesity medications and investigational agents: an obesity medicine association (OMA) clinical practice statement (CPS) 2022","author":"Bays","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide effects on cardiovascular outcomes in People with overweight or obesity (SELECT) rationale and design","volume":"229","author":"Ryan","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.obpill.2023.100056_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/03007995.2016.1251892","article-title":"Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects","volume":"33","author":"Bays","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.obpill.2023.100056_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12933-022-01508-6","article-title":"Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus","volume":"21","author":"Suzuki","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.obpill.2023.100056_bib24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.obpill.2023.100056_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12325-021-01994-2","article-title":"Chronic kidney disease and SGLT2 inhibitors: a review of the evolving treatment landscape","volume":"39","author":"Mende","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.obpill.2023.100056_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154918","article-title":"Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease","volume":"126","author":"Liu","year":"2022","journal-title":"Metabol: Clin Exp"},{"key":"10.1016\/j.obpill.2023.100056_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s13679-019-00335-3","article-title":"Metformin: mechanisms in human obesity and weight loss","volume":"8","author":"Yerevanian","year":"2019","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.obpill.2023.100056_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179738","article-title":"From diabetes to atherosclerosis: potential of metformin for management of cardiovascular disease","volume":"23","author":"Poznyak","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.obpill.2023.100056_bib29","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1161\/CIRCULATIONAHA.121.056756","article-title":"Effects of long-term metformin and lifestyle interventions on cardiovascular events in the diabetes prevention program and its outcome study","volume":"145","author":"Goldberg","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.obpill.2023.100056_bib30","author":"Bays"},{"key":"10.1016\/j.obpill.2023.100056_bib31","article-title":"Obesity Pillars roundtable: excessive weight reduction with highly effective anti-obesity medications (heAOMs)","volume":"4","author":"Bays","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib32","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1586\/14779072.4.6.871","article-title":"Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?","volume":"4","author":"Bays","year":"2006","journal-title":"Expet Rev Cardiovasc Ther"},{"key":"10.1016\/j.obpill.2023.100056_bib33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1586\/14779072.3.3.393","article-title":"Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything","volume":"3","author":"Bays","year":"2005","journal-title":"Expet Rev Cardiovasc Ther"},{"key":"10.1016\/j.obpill.2023.100056_bib34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1055\/s-0029-1192044","article-title":"Adipose tissue dysfunction in obesity","volume":"117","author":"Bluher","year":"2009","journal-title":"Exp Clin Endocrinol Diabetes : official journal"},{"key":"10.1016\/j.obpill.2023.100056_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.861350","article-title":"Harnessing the power of leptin: the biochemical link connecting obesity, diabetes, and cognitive decline","volume":"14","author":"Grasso","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.obpill.2023.100056_bib36","first-page":"676","article-title":"Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications","volume":"132","author":"Wysham","year":"2020","journal-title":"PGM (Postgrad Med)"},{"key":"10.1016\/j.obpill.2023.100056_bib37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bbalip.2009.08.006","article-title":"Glucolipotoxicity of the pancreatic beta cell","volume":"1801","author":"Poitout","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.obpill.2023.100056_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105522","article-title":"Adipose tissue secretion pattern influences beta-cell wellness in the transition from obesity to type 2 diabetes","volume":"23","author":"Biondi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.obpill.2023.100056_bib39","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1007\/s11010-021-04146-w","article-title":"Physiological effects of nutrients on insulin release by pancreatic beta cells","volume":"476","author":"Losada-Barrag\u00e1n","year":"2021","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.obpill.2023.100056_bib40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/jcp.22023","article-title":"Mitogen-activated protein kinase-activated protein kinase 2 (MK2) in skeletal muscle atrophy and hypertrophy","volume":"223","author":"Norrby","year":"2010","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.obpill.2023.100056_bib41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.biochi.2004.10.018","article-title":"The role of MAPKs in adipocyte differentiation and obesity","volume":"87","author":"Bost","year":"2005","journal-title":"Biochimie"},{"key":"10.1016\/j.obpill.2023.100056_bib42","first-page":"158","article-title":"Insulin--carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research","volume":"122","author":"Call","year":"2010","journal-title":"PGM (Postgrad Med)"},{"key":"10.1016\/j.obpill.2023.100056_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101618","article-title":"A\u00a0comprehensive review on MAPK: a promising therapeutic target in cancer","volume":"11","author":"Braicu","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.obpill.2023.100056_bib44","article-title":"Cancer and obesity: an obesity medicine association (OMA) clinical practice statement (CPS) 2022","volume":"3","author":"Lazarus","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.obpill.2023.100056_bib46","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.7150\/ijbs.27173","article-title":"The PI3K\/AKT pathway in obesity and type 2 diabetes","volume":"14","author":"Huang","year":"2018","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.obpill.2023.100056_bib47","article-title":"Ceramides in adipose tissue","volume":"11","author":"Li","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.obpill.2023.100056_bib48","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.3390\/cells11152310","article-title":"Importance of the microenvironment and mechanosensing in adipose tissue biology","volume":"11","author":"Lecoutre","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.obpill.2023.100056_bib49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.bbrc.2012.12.154","article-title":"ATF3 plays a role in adipocyte hypoxia-mediated mitochondria dysfunction in obesity","volume":"431","author":"Jang","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.obpill.2023.100056_bib50","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1038\/s41598-020-62665-w","article-title":"High glucose induces phosphorylation and oxidation of mitochondrial proteins in renal tubular cells: a proteomics approach","volume":"10","author":"Aluksanasuwan","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.obpill.2023.100056_bib51","doi-asserted-by":"crossref","first-page":"606","DOI":"10.5534\/wjmh.200163","article-title":"Macrophage and adipocyte mitochondrial dysfunction in obesity-induced metabolic diseases","volume":"39","author":"Wang","year":"2021","journal-title":"World J Mens Health"},{"key":"10.1016\/j.obpill.2023.100056_bib52","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4093\/dmj.2018.0221","article-title":"Mitochondrial dysfunction in adipocytes as a primary cause of adipose tissue inflammation","volume":"43","author":"Woo","year":"2019","journal-title":"J\u00a0Diabetes Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41419-017-0135-z","article-title":"Cellular death, reactive oxygen species (ROS) and diabetic complications","volume":"9","author":"Volpe","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.obpill.2023.100056_bib54","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.diabres.2007.01.071","article-title":"Impact of mitochondrial ROS production in the pathogenesis of insulin resistance","volume":"77","author":"Nishikawa","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.obpill.2023.100056_bib55","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/15733998113099990074","article-title":"Emerging role of JNK in insulin resistance","volume":"9","author":"Li","year":"2013","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.obpill.2023.100056_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.2040-4603.2019.tb00055.x","article-title":"Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus","volume":"9","author":"Burhans","year":"2018","journal-title":"Compr Physiol"},{"key":"10.1016\/j.obpill.2023.100056_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e07851","article-title":"Adiponectin gene polymorphisms associated with diabetes mellitus: a descriptive review","volume":"7","author":"Howlader","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.obpill.2023.100056_bib58","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2337\/db06-1680","article-title":"Direct free fatty acid uptake into human adipocytes in vivo: relation to body fat distribution","volume":"56","author":"Shadid","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.obpill.2023.100056_bib59","article-title":"The impact of fasting on adipose tissue metabolism","volume":"1868","author":"Kersten","year":"2023","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.obpill.2023.100056_bib60","doi-asserted-by":"crossref","first-page":"E653","DOI":"10.1152\/ajpendo.00620.2020","article-title":"100th anniversary of the discovery of insulin perspective: insulin and adipose tissue fatty acid metabolism","volume":"320","author":"Carpentier","year":"2021","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.obpill.2023.100056_bib61","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2337\/diabetes.52.3.675","article-title":"Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy","volume":"52","author":"Miles","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.obpill.2023.100056_bib62","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"The J Clin Invest"},{"key":"10.1016\/j.obpill.2023.100056_bib63","doi-asserted-by":"crossref","first-page":"610","DOI":"10.7150\/ijbs.29599","article-title":"Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer","volume":"15","author":"Divella","year":"2019","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.obpill.2023.100056_bib64","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008179","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis","volume":"96","author":"Dai","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.obpill.2023.100056_bib65","article-title":"Nonalcoholic fatty liver disease and obesity: an obesity medicine association (OMA) clinical practice statement (CPS) 2022","volume":"3","author":"Karjoo","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib66","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol Metab Syndrome"},{"key":"10.1016\/j.obpill.2023.100056_bib67","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3389\/fphar.2019.00877","article-title":"NAFLD and diabetes: two sides of the same coin? Rationale for gene-based personalized NAFLD treatment","volume":"10","author":"Xia","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.obpill.2023.100056_bib68","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/nutrit\/nuy001","article-title":"Fundamentals of glycogen metabolism for coaches and athletes","volume":"76","author":"Murray","year":"2018","journal-title":"Nutr Rev"},{"key":"10.1016\/j.obpill.2023.100056_bib69","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3389\/fendo.2018.00802","article-title":"Unraveling the regulation of hepatic gluconeogenesis","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.obpill.2023.100056_bib70","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4239\/wjd.v12.i5.556","article-title":"Renal gluconeogenesis in insulin resistance: a culprit for hyperglycemia in diabetes","volume":"12","author":"Sharma","year":"2021","journal-title":"World J Diabetes"},{"key":"10.1016\/j.obpill.2023.100056_bib71","first-page":"1","article-title":"Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes","volume":"33","author":"Hiyoshi","year":"2017","journal-title":"J\u00a0Biomed Res"},{"key":"10.1016\/j.obpill.2023.100056_bib72","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/cns.12866","article-title":"Insulin receptor in the brain: mechanisms of activation and the role in the CNS pathology and treatment","volume":"24","author":"Pomytkin","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.obpill.2023.100056_bib73","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1586\/14779072.6.3.343","article-title":"Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity","volume":"6","author":"Bays","year":"2008","journal-title":"Expet Rev Cardiovasc Ther"},{"issue":"Suppl 3","key":"10.1016\/j.obpill.2023.100056_bib74","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.12154","article-title":"The immune cells in adipose tissue","volume":"15","author":"Ferrante","year":"2013","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib75","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13287-017-0598-y","article-title":"Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation","volume":"8","author":"Bora","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.obpill.2023.100056_bib76","article-title":"Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines","volume":"2013","author":"Makki","year":"2013","journal-title":"ISRN Inflamm"},{"key":"10.1016\/j.obpill.2023.100056_bib77","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nrendo.2014.44","article-title":"The pathophysiology of hypertension in patients with obesity","volume":"10","author":"DeMarco","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.obpill.2023.100056_bib78","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/JOE-14-0283","article-title":"The role of adipose tissue immune cells in obesity and low-grade inflammation","volume":"222","author":"Mraz","year":"2014","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.obpill.2023.100056_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101642","article-title":"Adipose tissue macrophages: regulators of adipose tissue immunometabolism during obesity","author":"Nance","year":"2022","journal-title":"Mol Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/cells11091424","article-title":"New insights into adipose tissue macrophages in obesity and insulin resistance","volume":"11","author":"Cai","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.obpill.2023.100056_bib81","first-page":"29","article-title":"Obesity-induced insulin resistance and macrophage infiltration of the adipose tissue: a vicious cycle","volume":"10","author":"Lee","year":"2019","journal-title":"J\u00a0Diabet Invest"},{"key":"10.1016\/j.obpill.2023.100056_bib82","article-title":"Stress, psychiatric disease, and obesity: an obesity medicine association (OMA) clinical practice statement (CPS) 2022","volume":"4","author":"Christensen","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib83","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/21623945.2022.2107786","article-title":"MAPKs\/AP-1, not NF-kappaB, is responsible for MCP-1 production in TNF-alpha-activated adipocytes","volume":"11","author":"Zhang","year":"2022","journal-title":"Adipocyte"},{"key":"10.1016\/j.obpill.2023.100056_bib84","doi-asserted-by":"crossref","first-page":"e2412","DOI":"10.1038\/cddis.2016.286","article-title":"TRAIL (TNF-related apoptosis-inducing ligand) inhibits human adipocyte differentiation via caspase-mediated downregulation of adipogenic transcription factors","volume":"7","author":"Zoller","year":"2016","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.obpill.2023.100056_bib85","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jacl.2015.12.002","article-title":"Lipids and bariatric procedures part 1 of 2: scientific statement from the national lipid association, American society for metabolic and bariatric surgery, and obesity medicine association: full report","volume":"10","author":"Bays","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.obpill.2023.100056_bib86","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3803\/EnM.2018.33.1.105","article-title":"Pioglitazone attenuates palmitate-induced inflammation and endoplasmic reticulum stress in pancreatic \u03b2-cells","volume":"33","author":"Hong","year":"2018","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.obpill.2023.100056_bib87","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10753-013-9746-4","article-title":"Increased concentration of C-reactive protein in obese patients with type 2 diabetes is associated with obesity and presence of diabetes but not with macrovascular and microvascular complications or glycemic control","volume":"37","author":"Fronczyk","year":"2014","journal-title":"Inflammation"},{"key":"10.1016\/j.obpill.2023.100056_bib88","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1615\/CritRevEukaryotGeneExpr.2017019712","article-title":"Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus","volume":"27","author":"Rehman","year":"2017","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"10.1016\/j.obpill.2023.100056_bib89","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.molmet.2017.04.011","article-title":"The glucoregulatory actions of leptin","volume":"6","author":"D'Souza","year":"2017","journal-title":"Mol Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/nu11112704","article-title":"Leptin, obesity, and leptin resistance: where are we 25 Years later?","volume":"11","author":"Izquierdo","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.obpill.2023.100056_bib91","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/aps.2018.40","article-title":"Leptin, cardiovascular diseases and type 2 diabetes mellitus","volume":"39","author":"Katsiki","year":"2018","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"10.1016\/j.obpill.2023.100056_bib92","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000500201","article-title":"Persistent leptin signaling in the arcuate nucleus impairs hypothalamic insulin signaling and glucose homeostasis in obese mice","volume":"109","author":"Balland","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.obpill.2023.100056_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/nu14224735","article-title":"Adipose tissue dysfunction in obesity: role of mineralocorticoid receptor","volume":"14","author":"Parasiliti-Caprino","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.obpill.2023.100056_bib94","first-page":"21","article-title":"Adipokines and obesity. Potential link to metabolic disorders and chronic complications","author":"Zorena","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.obpill.2023.100056_bib95","first-page":"37","article-title":"The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome","volume":"15","author":"Stimson","year":"2013","journal-title":"Horm Mol Biol Clin Invest"},{"key":"10.1016\/j.obpill.2023.100056_bib96","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ecl.2013.10.005","article-title":"Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism","volume":"43","author":"Geer","year":"2014","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.1016\/j.obpill.2023.100056_bib97","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1530\/JOE-15-0117","article-title":"11\u03b2-HSD1 reduces metabolic efficacy and adiponectin synthesis in hypertrophic adipocytes","volume":"225","author":"Koh","year":"2015","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.obpill.2023.100056_bib98","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/liv.15005","article-title":"PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.obpill.2023.100056_bib99","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/ijo.2017.31","article-title":"Subcutaneous fat loss is greater than visceral fat loss with diet and exercise, weight-loss promoting drugs and bariatric surgery: a critical review and meta-analysis","volume":"41","author":"Merlotti","year":"2017","journal-title":"Int J Obes"},{"key":"10.1016\/j.obpill.2023.100056_bib100","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/er.2017-00211","article-title":"Metabolic flexibility as an adaptation to energy resources and requirements in health and disease","volume":"39","author":"Smith","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.obpill.2023.100056_bib101","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabol: Clin Exp"},{"key":"10.1016\/j.obpill.2023.100056_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.112","article-title":"The metabolic basis of nonalcoholic steatohepatitis","volume":"3","author":"Chakravarthy","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.obpill.2023.100056_bib103","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12902-021-00687-9","article-title":"Relationship between insulin sensitivity and gene expression in human skeletal muscle","volume":"21","author":"Parikh","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.obpill.2023.100056_bib104","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.cmet.2017.04.015","article-title":"Metabolic flexibility in health and disease","volume":"25","author":"Goodpaster","year":"2017","journal-title":"Cell Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib105","first-page":"1934","article-title":"Role of skeletal muscle lipids in the pathogenesis of insulin resistance of obesity and type 2 diabetes","volume":"12","author":"Gilbert","year":"2021","journal-title":"J\u00a0Diabet Invest"},{"key":"10.1016\/j.obpill.2023.100056_bib106","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1210\/jc.2003-030723","article-title":"Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach","volume":"89","author":"Bays","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib107","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molmet.2014.01.011","article-title":"On ceramides, other sphingolipids and impaired glucose homeostasis","volume":"3","author":"Larsen","year":"2014","journal-title":"Mol Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib108","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1038\/s41467-022-34095-x","article-title":"Altered glycolysis triggers impaired mitochondrial metabolism and mTORC1 activation in diabetic \u03b2-cells","volume":"13","author":"Haythorne","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.obpill.2023.100056_bib109","first-page":"646","article-title":"Roles of sphingolipid metabolism in pancreatic beta cell dysfunction induced by lipotoxicity","volume":"3","author":"Veret","year":"2014","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.obpill.2023.100056_bib110","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.cmet.2018.07.003","article-title":"Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for beta cell recovery","volume":"28","author":"Taylor","year":"2018","journal-title":"Cell Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib111","article-title":"Obesity history, physical exam, laboratory, body composition, and energy expenditure: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022","volume":"1","author":"Burridge","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib112","article-title":"Nutrition and physical activity: an obesity medicine association (OMA) clinical practice statement 2022","volume":"1","author":"Alexander","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib113","article-title":"Obesity pillars roundtable: obesity and individuals from the Mediterranean region and Middle East","volume":"2","author":"Bays","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib114","article-title":"Behavior, motivational interviewing, eating disorders, and obesity management technologies: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022","volume":"2","author":"Freshwater","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib115","article-title":"Obesity pillars roundtable: phentermine \u2013 Past, present, and future","volume":"3","author":"Bays","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib116","article-title":"Concomitant medications, functional foods, and supplements: an obesity medicine association (OMA) clinical practice statement (CPS) 2022","volume":"2","author":"Tondt","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib117","article-title":"Weight-centric treatment of type 2 diabetes mellitus","volume":"4","author":"Ghusn","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib118","article-title":"Bariatric surgery, gastrointestinal hormones, and the microbiome: an obesity medicine association (OMA) clinical practice statement (CPS) 2022","volume":"2","author":"Shetye","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib119","article-title":"Assessment, differential diagnosis, and initial clinical evaluation of the pediatric patient with obesity: an Obesity Medical Association (OMA) Clinical Practice Statement 2022","volume":"1","author":"Cuda","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib120","article-title":"Social consequences and genetics for the child with overweight and obesity: an obesity medicine association (OMA) clinical practice statement 2022","volume":"3","author":"Cuda","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib121","article-title":"Nutritional and activity recommendations for the child with normal weight, overweight, and obesity with consideration of food insecurity: an Obesity Medical Association (OMA) Clinical Practice Statement 2022","volume":"2","author":"Browne","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib122","article-title":"Metabolic, behavioral health, and disordered eating comorbidities associated with obesity in pediatric patients: an Obesity Medical Association (OMA) Clinical Practice Statement 2022","volume":"3","author":"Cuda","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib123","article-title":"Obesity Pillars roundtable: metabolic and bariatric surgery in children and adolescents","volume":"3","author":"Cuda","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib124","article-title":"Obesity pillars roundtable: obesity and diversity","volume":"1","author":"Bays","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib125","article-title":"Obesity pillars roundtable: obesity and east asians","volume":"2","author":"Bays","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib126","article-title":"Obesity pillars roundtable: obesity and South Asians","volume":"1","author":"Bays","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib127","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamainternmed.2019.0899","article-title":"Association of step volume and intensity with all-cause mortality in older women","volume":"179","author":"Lee","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.obpill.2023.100056_bib128","article-title":"Association of longitudinal activity measures and diabetes risk: an analysis from the NIH All of Us Research Program","author":"Perry","year":"2022","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib129","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1249\/MSS.0000000000001932","article-title":"Daily step counts for measuring physical activity exposure and its relation to health","volume":"51","author":"Kraus","year":"2019","journal-title":"Med Sci Sports Exerc"},{"issue":"2","key":"10.1016\/j.obpill.2023.100056_bib130","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1161\/CIRCULATIONAHA.122.061288","article-title":"Prospective association of daily steps with cardiovascular disease: a harmonized meta-analysis","volume":"147","author":"Paluch","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.obpill.2023.100056_bib131","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.2020.1382","article-title":"Association of daily step count and step intensity with mortality among US adults","volume":"323","author":"Saint-Maurice","year":"2020","journal-title":"JAMA, J Am Med Assoc"},{"key":"10.1016\/j.obpill.2023.100056_bib132","article-title":"Sleep-disordered breathing, sleep apnea, and other obesity-related sleep disorders: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022","volume":"4","author":"Pennings","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2023.100056_bib133","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.2337\/dc23-S008","article-title":"Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.obpill.2023.100056_bib136","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"Cardiovascular disease and risk management: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.obpill.2023.100056_bib137","doi-asserted-by":"crossref","DOI":"10.1177\/2042018820980225","article-title":"Should metformin remain the first-line therapy for treatment of type 2 diabetes?","volume":"12","author":"Baker","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.obpill.2023.100056_bib138","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgac759","article-title":"Predictors of metformin failure: repurposing electronic health record data to identify high-risk patients","author":"Bielinski","year":"2023","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib139","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/FJC.0000000000001299","article-title":"A\u00a0novel dual incretin agent, tirzepatide (LY3298176), for the treatment of type 2 diabetes mellitus and cardiometabolic health","volume":"80","author":"Bucheit","year":"2022","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.obpill.2023.100056_bib140","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s11883-022-01062-2","article-title":"GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far?","volume":"24","author":"Pedrosa","year":"2022","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.obpill.2023.100056_bib141","first-page":"1160","article-title":"Bariatric surgery for the management of type 2 diabetes mellitus-current trends and challenges: a review article","volume":"14","author":"Alqunai","year":"2022","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.obpill.2023.100056_bib142","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.obpill.2023.100056_bib143","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA, J Am Med Assoc"},{"issue":"4","key":"10.1016\/j.obpill.2023.100056_bib144","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE -TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.obpill.2023.100056_bib145","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1210\/jc.2018-00040","article-title":"Cardiovascular benefits of acarbose vs sulfonylureas in patients with type 2 diabetes treated with metformin","volume":"103","author":"Hsu","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib146","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.118.034516","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke","volume":"138","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.obpill.2023.100056_bib147","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.obpill.2023.100056_bib148","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2023.100056_bib150","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2023.100056_bib151","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","article-title":"Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Holman","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.obpill.2023.100056_bib152","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2023.100056_bib153","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-022-01575-9","article-title":"Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes","volume":"21","author":"Davies","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.obpill.2023.100056_bib154","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645566","article-title":"Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6","volume":"12","author":"Nauck","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.obpill.2023.100056_bib155","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2023.100056_bib156","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and treatment of lipodystrophy: a step-by-step approach","volume":"42","author":"Ara\u00fajo-Vilar","year":"2019","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.obpill.2023.100056_bib157","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7861\/clinmedicine.19-1-37","article-title":"Calorie restriction for long-term remission of type 2 diabetes","volume":"19","author":"Taylor","year":"2019","journal-title":"Clin Med"},{"key":"10.1016\/j.obpill.2023.100056_bib158","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/17446651.2016.1239525","article-title":"Calorie restriction and reversal of type 2 diabetes","volume":"11","author":"Taylor","year":"2016","journal-title":"Expet Rev Endocrinol Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib159","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1172\/JCI200422028","article-title":"The case of visceral fat: argument for the defense","volume":"113","author":"Klein","year":"2004","journal-title":"The J Clin Invest"},{"key":"10.1016\/j.obpill.2023.100056_bib160","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1038\/nutd.2012.5","article-title":"Effect of moderate weight loss on hepatic, pancreatic and visceral lipids in obese subjects","volume":"2","author":"Rossi","year":"2012","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.obpill.2023.100056_bib161","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00125-021-05577-2","article-title":"Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission","volume":"65","author":"Churuangsuk","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.obpill.2023.100056_bib162","article-title":"Effect of an intermittent calorie-restricted diet on type 2 diabetes remission: a randomized controlled trial","author":"Yang","year":"2022","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102452","article-title":"Diabetes reversal: update on current knowledge and proposal of prediction score parameters for diabetes remission","volume":"16","author":"Singla","year":"2022","journal-title":"Diabetes Metabol Syndr"},{"key":"10.1016\/j.obpill.2023.100056_bib164","first-page":"21","article-title":"Prevention of diabetes and cardiovascular disease in obesity","author":"La Sala","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.obpill.2023.100056_bib165","doi-asserted-by":"crossref","first-page":"m4743","DOI":"10.1136\/bmj.m4743","article-title":"Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data","volume":"372","author":"Goldenberg","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.obpill.2023.100056_bib166","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial","volume":"7","author":"Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.obpill.2023.100056_bib167","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2337\/dc21-2136","article-title":"Incidence and characteristics of remission of type 2 diabetes in England: a cohort study using the national diabetes audit","volume":"45","author":"Holman","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.obpill.2023.100056_bib168","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s11695-014-1285-z","article-title":"Correlation between postoperative weight loss and diabetes mellitus remission: a meta-analysis","volume":"24","author":"Yan","year":"2014","journal-title":"Obes Surg"},{"key":"10.1016\/j.obpill.2023.100056_bib169","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4239\/wjd.v12.i7.1093","article-title":"Diabetes remission after bariatric surgery","volume":"12","author":"Chumakova-Orin","year":"2021","journal-title":"World J Diabetes"},{"key":"10.1016\/j.obpill.2023.100056_bib170","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","article-title":"Current therapies and new developments in NASH","volume":"71","author":"Dufour","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.obpill.2023.100056_bib171","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13679-022-00474-0","article-title":"Anti-obesity medications for the management of nonalcoholic fatty liver disease","volume":"11","author":"Polyzos","year":"2022","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.obpill.2023.100056_bib172","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa0804748","article-title":"Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates","volume":"360","author":"Sacks","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2023.100056_bib173","unstructured":"Zhao D, Guallar E, Woolf TB, Martin L, Lehmann H, Coughlin J, et\u00a0al. Association of eating and sleeping intervals with weight change over time: the Daily24 cohort. J Am Heart Assoc.0:e026484."},{"key":"10.1016\/j.obpill.2023.100056_bib174","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa2114833","article-title":"Calorie restriction with or without time-restricted eating in weight loss","volume":"386","author":"Liu","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2023.100056_bib175","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev-nutr-121415-112624","article-title":"The macronutrients, appetite, and energy intake","volume":"36","author":"Carreiro","year":"2016","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.obpill.2023.100056_bib176","doi-asserted-by":"crossref","DOI":"10.3390\/nu11020340","article-title":"Effect of macronutrient composition on appetite hormone responses in adolescents with obesity","volume":"11","author":"Nguo","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.obpill.2023.100056_bib177","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1743-7075-3-7","article-title":"Comparison of isocaloric very low carbohydrate\/high saturated fat and high carbohydrate\/low saturated fat diets on body composition and cardiovascular risk","volume":"3","author":"Noakes","year":"2006","journal-title":"Nutr Metabol"},{"key":"10.1016\/j.obpill.2023.100056_bib178","article-title":"Potential benefits of sodium-glucose transporter-2 inhibitors in the symptomatic and functional status of patients with heart failure: a systematic review and meta-analysis","volume":"14","author":"Bhalla","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.obpill.2023.100056_bib179","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1185\/03007990802710422","article-title":"From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus","volume":"25","author":"Bays","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.obpill.2023.100056_bib180","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/oby.20663","article-title":"Canagliflozin: effects in overweight and obese subjects without diabetes mellitus","volume":"22","author":"Bays","year":"2014","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2023.100056_bib181","series-title":"Clinical practice guidelines we can trust","author":"Graham","year":"2011"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368123000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368123000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:21:34Z","timestamp":1762644094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368123000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":178,"alternative-id":["S2667368123000025"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2023.100056","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2023.100056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100056"}}